These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9196148)

  • 1. Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer.
    Guadagnoli E; Shapiro C; Gurwitz JH; Silliman RA; Weeks JC; Borbas C; Soumerai SB
    J Clin Oncol; 1997 Jun; 15(6):2338-44. PubMed ID: 9196148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community-based assessment of adjuvant hormone therapy in women with breast cancer, 1991-1997.
    Du XL; Key CR; Osborne C
    Breast J; 2004; 10(5):433-9. PubMed ID: 15327498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based study on variations in the use of adjuvant systemic therapy on postmenopausal patients with early stage breast cancer.
    Nagel G; Röhrig B; Hoyer H; Wedding U; Katenkamp D
    J Cancer Res Clin Oncol; 2003 Mar; 129(3):183-91. PubMed ID: 12709795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer treatment guidelines in older women.
    Giordano SH; Hortobagyi GN; Kau SW; Theriault RL; Bondy ML
    J Clin Oncol; 2005 Feb; 23(4):783-91. PubMed ID: 15681522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
    Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
    J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
    Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.
    Sukel MP; van de Poll-Franse LV; Nieuwenhuijzen GA; Vreugdenhil G; Herings RM; Coebergh JW; Voogd AC
    Eur J Cancer; 2008 Sep; 44(13):1846-54. PubMed ID: 18640030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Lee JH; Recht A
    J Clin Oncol; 2003 Jun; 21(12):2260-7. PubMed ID: 12805324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
    Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
    Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of relapse in breast cancer: changes over time.
    Yerushalmi R; Woods R; Kennecke H; Speers C; Knowling M; Gelmon K
    Breast Cancer Res Treat; 2010 Apr; 120(3):753-9. PubMed ID: 19701704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.
    Koopal C; Janssen-Heijnen ML; van de Wouw AJ; van den Bergh JP
    Breast; 2015 Apr; 24(2):153-8. PubMed ID: 25618224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
    Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
    Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.